Brief: Cerevel Therapeutics Announces Positive Topline Results For Tavapadon In Phase 3 Adjunctive Trial For People Living With Parkinson’S Disease

Cerevel Therapeutics Holdings

18/04/2024 13:27

April 18 (Reuters) - Cerevel Therapeutics Holdings Inc
 CERE.O :
    * CEREVEL THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS
FOR
TAVAPADON IN PHASE 3 ADJUNCTIVE TRIAL FOR PEOPLE LIVING WITH
PARKINSON’S DISEASE
    * CEREVEL THERAPEUTICS HOLDINGS INC: TAVAPADON MET PRIMARY
ENDPOINT IN PIVOTAL PHASE 3 TEMPO-3 ADJUNCTIVE TRIAL
    * CEREVEL THERAPEUTICS HOLDINGS INC - TAVAPADON MET PRIMARY
ENDPOINT IN PIVOTAL PHASE 3
    * CEREVEL THERAPEUTICS HOLDINGS INC - RESULTS FROM TAVAPADON
PHASE
3 MONOTHERAPY TRIALS (TEMPO-1 AND TEMPO-2) ARE EXPECTED IN
SECOND HALF OF 2024
    * CEREVEL: STATISTICALLY SIGNIFICANT REDUCTION IN "OFF"
TIME, KEY
SECONDARY ENDPOINT, OBSERVED FOR TAVAPADON TREATMENT ARM
    * CEREVEL THERAPEUTICS HOLDINGS INC - TAVAPADON WAS
GENERALLY WELL
TOLERATED

Source text for Eikon:  ID:nGNX4HyTTx 
Further company coverage:  CERE.O